EGFR overexpression in malignant pleural mesothelioma

An immunohistochemical and molecular study with clinico-pathological correlations

A. Destro, G. L. Ceresoli, M. Falleni, P. A. Zucali, E. Morenghi, P. Bianchi, C. Pellegrini, N. Cordani, V. Vaira, M. Alloisio, A. Rizzi, S. Bosari, M. Roncalli

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial malignancies, against which some antitumoral drugs have been developed. There is a lack of information as to EGFR expression in malignant pleural mesothelioma (MPM), an aggressive and fatal cancer poorly responsive to current oncological treatments. Our aim was to: (a) compare EGFR immunohistochemical expression with mRNA levels measured by real time PCR; (b) assess the relationships between EGFR expression and clinico-pathological data including survival; (c) analyze the EGFR mutations. We developed an immunohistochemical method of EGFR evaluation based on the number of immunoreactive cells and staining intensity in 61 MPMs. EGFR immunoreactivity was documented in 34/61 (55.7%) cases. A significant correlation between EGFR protein and mRNA levels (p = 0.0077) was found, demonstrating the reliability of our quantification method of EGFR membrane expression. Radically resected patients (p = 0.005) and those with epithelial histotype (p = 0.048) showed an increased survival. No statistical correlation between EGFR immunoreactivity and patients survival was observed. No EGFR mutation was documented. This study documents EGFR overexpression in MPM at the protein and the transcriptional levels; it proposes a reliable method for EGFR expression evaluation in MPM. EGFR levels are not associated with clinico-pathological features of patients, including survival.

Original languageEnglish
Pages (from-to)207-215
Number of pages9
JournalLung Cancer
Volume51
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Epidermal Growth Factor Receptor
Survival
Malignant Mesothelioma
Messenger RNA
Mutation
Real-Time Polymerase Chain Reaction
Neoplasms
Proteins
Cell Count
Staining and Labeling

Keywords

  • EGFR
  • Immunohistochemistry
  • Mesothelioma
  • Prognostic factors
  • Real-time PCR

ASJC Scopus subject areas

  • Oncology

Cite this

EGFR overexpression in malignant pleural mesothelioma : An immunohistochemical and molecular study with clinico-pathological correlations. / Destro, A.; Ceresoli, G. L.; Falleni, M.; Zucali, P. A.; Morenghi, E.; Bianchi, P.; Pellegrini, C.; Cordani, N.; Vaira, V.; Alloisio, M.; Rizzi, A.; Bosari, S.; Roncalli, M.

In: Lung Cancer, Vol. 51, No. 2, 02.2006, p. 207-215.

Research output: Contribution to journalArticle

@article{7ab6ba083acd4070b270ef9a51358a81,
title = "EGFR overexpression in malignant pleural mesothelioma: An immunohistochemical and molecular study with clinico-pathological correlations",
abstract = "The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial malignancies, against which some antitumoral drugs have been developed. There is a lack of information as to EGFR expression in malignant pleural mesothelioma (MPM), an aggressive and fatal cancer poorly responsive to current oncological treatments. Our aim was to: (a) compare EGFR immunohistochemical expression with mRNA levels measured by real time PCR; (b) assess the relationships between EGFR expression and clinico-pathological data including survival; (c) analyze the EGFR mutations. We developed an immunohistochemical method of EGFR evaluation based on the number of immunoreactive cells and staining intensity in 61 MPMs. EGFR immunoreactivity was documented in 34/61 (55.7{\%}) cases. A significant correlation between EGFR protein and mRNA levels (p = 0.0077) was found, demonstrating the reliability of our quantification method of EGFR membrane expression. Radically resected patients (p = 0.005) and those with epithelial histotype (p = 0.048) showed an increased survival. No statistical correlation between EGFR immunoreactivity and patients survival was observed. No EGFR mutation was documented. This study documents EGFR overexpression in MPM at the protein and the transcriptional levels; it proposes a reliable method for EGFR expression evaluation in MPM. EGFR levels are not associated with clinico-pathological features of patients, including survival.",
keywords = "EGFR, Immunohistochemistry, Mesothelioma, Prognostic factors, Real-time PCR",
author = "A. Destro and Ceresoli, {G. L.} and M. Falleni and Zucali, {P. A.} and E. Morenghi and P. Bianchi and C. Pellegrini and N. Cordani and V. Vaira and M. Alloisio and A. Rizzi and S. Bosari and M. Roncalli",
year = "2006",
month = "2",
doi = "10.1016/j.lungcan.2005.10.016",
language = "English",
volume = "51",
pages = "207--215",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - EGFR overexpression in malignant pleural mesothelioma

T2 - An immunohistochemical and molecular study with clinico-pathological correlations

AU - Destro, A.

AU - Ceresoli, G. L.

AU - Falleni, M.

AU - Zucali, P. A.

AU - Morenghi, E.

AU - Bianchi, P.

AU - Pellegrini, C.

AU - Cordani, N.

AU - Vaira, V.

AU - Alloisio, M.

AU - Rizzi, A.

AU - Bosari, S.

AU - Roncalli, M.

PY - 2006/2

Y1 - 2006/2

N2 - The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial malignancies, against which some antitumoral drugs have been developed. There is a lack of information as to EGFR expression in malignant pleural mesothelioma (MPM), an aggressive and fatal cancer poorly responsive to current oncological treatments. Our aim was to: (a) compare EGFR immunohistochemical expression with mRNA levels measured by real time PCR; (b) assess the relationships between EGFR expression and clinico-pathological data including survival; (c) analyze the EGFR mutations. We developed an immunohistochemical method of EGFR evaluation based on the number of immunoreactive cells and staining intensity in 61 MPMs. EGFR immunoreactivity was documented in 34/61 (55.7%) cases. A significant correlation between EGFR protein and mRNA levels (p = 0.0077) was found, demonstrating the reliability of our quantification method of EGFR membrane expression. Radically resected patients (p = 0.005) and those with epithelial histotype (p = 0.048) showed an increased survival. No statistical correlation between EGFR immunoreactivity and patients survival was observed. No EGFR mutation was documented. This study documents EGFR overexpression in MPM at the protein and the transcriptional levels; it proposes a reliable method for EGFR expression evaluation in MPM. EGFR levels are not associated with clinico-pathological features of patients, including survival.

AB - The epidermal growth factor receptor (EGFR) is overexpressed in many epithelial malignancies, against which some antitumoral drugs have been developed. There is a lack of information as to EGFR expression in malignant pleural mesothelioma (MPM), an aggressive and fatal cancer poorly responsive to current oncological treatments. Our aim was to: (a) compare EGFR immunohistochemical expression with mRNA levels measured by real time PCR; (b) assess the relationships between EGFR expression and clinico-pathological data including survival; (c) analyze the EGFR mutations. We developed an immunohistochemical method of EGFR evaluation based on the number of immunoreactive cells and staining intensity in 61 MPMs. EGFR immunoreactivity was documented in 34/61 (55.7%) cases. A significant correlation between EGFR protein and mRNA levels (p = 0.0077) was found, demonstrating the reliability of our quantification method of EGFR membrane expression. Radically resected patients (p = 0.005) and those with epithelial histotype (p = 0.048) showed an increased survival. No statistical correlation between EGFR immunoreactivity and patients survival was observed. No EGFR mutation was documented. This study documents EGFR overexpression in MPM at the protein and the transcriptional levels; it proposes a reliable method for EGFR expression evaluation in MPM. EGFR levels are not associated with clinico-pathological features of patients, including survival.

KW - EGFR

KW - Immunohistochemistry

KW - Mesothelioma

KW - Prognostic factors

KW - Real-time PCR

UR - http://www.scopus.com/inward/record.url?scp=31344449869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31344449869&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.10.016

DO - 10.1016/j.lungcan.2005.10.016

M3 - Article

VL - 51

SP - 207

EP - 215

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -